Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 74

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 74
---
 to percentage royalty payments ranging from 5% to 15% which may decrease or increase up to 30% if the Company challenges the validity of the patents under the agreement, depending on the result of such challenge. Further, pursuant to the Aexon Agreement, the Company has agreed to pay Aexon a percentage of license fees, milestones and royalties received from sublicensees, ranging between 5% and 15% which may decrease or increase up to 30% if the Company challenges the validity of the patents under the agreement, depending on the result of such challenge. For the six months ended June 30, 2025, the Company recorded fees to Aexon of $ 50,000which is included in research and development expenses on the statement of operating and comprehensive loss. In October 2024, the Company entered into a consulting agreement with Ms. Nicole Fernandez -McGovern, the Company’s current Chief Financial Officer, pursuant to which the Company agreed to pay Mr. Fernandez -McGoverna monthly retainer for her services of $ 18,000per month. For the six months ended June 30, 2025, the Company recorded fees to Ms. Fernandez -McGovernof $ 108,000which is included in general and administrative expenses on the statement of operating and comprehensive loss.

Note 8

Revisions of previously issued financial statements:

The Company identified an error in the classification of Preferred Shares and common shares within shareholders’ equity on the Consolidated Balance Sheets as of December 31, 2024. The error was limited to the line item presentation of “preferred shares” and “common shares” and did not affect total shareholders’ equity (deficit), the consolidated statements of operations, the consolidated statements of equity, the consolidated statements of cash flows, or any other financial statement captions.

The Consolidated Balance Sheets have been revised to correct the presentation of preferred shares and common shares as of December 31, 2024.

The table below summarizes the effect of the revision correcting the error on the Company’s previously issued financial statements as of December 31, 2024 (such revisions are prior to the retrospective restatement of the change in par value equally from CHF ($) per share to CHF ($) per share, with the released amounts to be allocated to the Company’s reserves):

| Shareholders’ Equity (Deficit)                                                                              |     | As Previously 
 Reported      |             |   |     | Adjustment |            |   |     | As Revised |             |   |